We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

82 hedge funds and large institutions have $790M invested in Avidity Biosciences in 2020 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 23 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

107% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 14

53% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 15

22% more funds holding

Funds holding: 67 → 82 (+15)

10.5% more ownership

Funds ownership: 72% → 82.5% (+11%)

5% more capital invested

Capital invested by funds: $755M → $790M (+$34.5M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
82
Holders Change
+15
Holders Change %
+22.39%
% of All Funds
1.45%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
29
Increased
23
Reduced
15
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
ACM
Alethea Capital Management
Washington
+$45.8M
2
BlackRock
BlackRock
New York
+$21.4M
3
State Street
State Street
Massachusetts
+$12.7M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$11.8M
5
TG
TCW Group
California
+$5.34M

Top Sellers

1
PHS
PFM Health Sciences
California
-$11M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$6.03M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$5.08M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$3.2M
5
ACH
ArrowMark Colorado Holdings
Colorado
-$2.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$102M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$87.4M +$11.8M +405,304 +13%
CAM
3
Cormorant Asset Management
Massachusetts
$62.9M -$1.46M -49,999 -2%
EC
4
EcoR1 Capital
California
$53.7M – – –
BlackRock
5
BlackRock
New York
$51.8M +$21.4M +734,652 +57%
ACM
6
Alethea Capital Management
Washington
$40.1M +$45.8M +1,571,160 New
Federated Hermes
7
Federated Hermes
Pennsylvania
$36.5M +$4.61M +158,000 +12%
PA
8
Perceptive Advisors
New York
$31.5M – – –
MCMC
9
Matrix Capital Management Company
New Hampshire
$30.6M – – –
BC
10
Boxer Capital
California
$28.6M – – –
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$24.1M -$374K -12,813 -1%
Alkeon Capital Management
12
Alkeon Capital Management
New York
$22.3M – – –
Victory Capital Management
13
Victory Capital Management
Texas
$21.8M +$1.46M +49,925 +6%
Vanguard Group
14
Vanguard Group
Pennsylvania
$20.8M +$1.9M +65,055 +9%
State Street
15
State Street
Massachusetts
$17.4M +$12.7M +436,557 +179%
LGM
16
Logos Global Management
California
$17.1M -$1.46M -50,000 -7%
ACA
17
Avoro Capital Advisors
New York
$13.9M – – –
Wellington Management Group
18
Wellington Management Group
Massachusetts
$13.8M -$6.03M -206,692 -28%
AWA
19
Aaron Wealth Advisors
Illinois
$13.4M +$15.3M +524,239 New
DM
20
Deerfield Management
New York
$11.6M -$589K -20,213 -4%
OCA
21
Octagon Capital Advisors
New York
$11M +$12.5M +430,041 New
HA
22
HHLR Advisors
Cayman Islands
$10.8M – – –
Geode Capital Management
23
Geode Capital Management
Massachusetts
$6.78M -$147K -5,049 -2%
ACP
24
Acuta Capital Partners
California
$6.28M +$327K +11,200 +5%
Goldman Sachs
25
Goldman Sachs
New York
$5.72M +$3.59M +123,026 +122%
1
2 3 4

RNAM Hedge Fund Activity: Q4 2020 in Review

82 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q4 2020, worth a combined $790M — up 4.6% from $755M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new RNAM positions and 14 closed out — a net gain of 15 holders — while 23 added to existing stakes and 15 trimmed.

The largest buyer was Alethea Capital Management, opening a new position worth an estimated $45.8M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $11M sold.

  • 82 institutional investors held Avidity Biosciences (RNAM) as of Q4 2020, up from 67 in Q3 2020.
  • Funds reported $790M of Avidity Biosciences stock for Q4 2020, up 4.6% quarter-over-quarter.
  • 29 funds opened new Avidity Biosciences positions in Q4 2020 and 14 closed out, a net change of +15 holders.
  • The largest Avidity Biosciences buyer in Q4 2020 was Alethea Capital Management, an estimated $45.8M added.
  • The largest Avidity Biosciences seller in Q4 2020 was PFM Health Sciences, an estimated $11M sold.

Based on aggregated 13F filings for Q4 2020.